SGSergio Garcia-Gomez

Sergio Garcia-Gomez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sergio Garcia-Gomez has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prolonged electrocardiographic monitorization with a wearable system after an embolic stroke of undetermined source

    by D De Castro, J T R Jorge Toquero, D J S Diego Jimenez, E G I Eusebio Garcia-Izquierdo, V C U Victor Castro-Urda, C A A Cristina Aguilera-Agudo, D G R Daniel Garcia-Rodriguez, F H T Fernando Hernandez-Terciado, P V M Paula Vela-Martin, P R P Paloma Remior, et al.

    Funding Acknowledgements: Type of funding sources: None. Background: Embolic cerebrovascular events that remain of unknown etiology after careful diagnostic evaluation are known as Embolic Strokes of Undetermined Source (ESUS). Subclinical atrial fibrillation (AF) is an important cause of ESUS. Purpose: Our aims were to analyze the global diagnostic yield of a prolonged cardiac monitoring wearable system (PCMw) after an ESUS to detect AF and factors associated with it, including the time frame from the ESUS event to PCMw initiation. Methods: We retrospectively analyzed 200 ECG recordings (3-leads, 30 days duration) by means of a PCMw in patients with an ESUS to detect AF lasting longer than 30 seconds, between 2017-2021. Results: AF was detected in 21 patients (10,5 %). Patients with AF had more left atrial enlargement (OR=4,22 [1.59-6.85]; p=0.01) and atrial arrythmias in the initial 24-h Holter during hospitalization (OR=5,73 [2.03-16,49]; p=0.001). The detection of AF was significatively higher if the PCMw was worn within the first 30 days after the ESUS compared to beyond 30 days (17% vs 10,3%; p=0,002). Conclusion: PCMw represents a feasible non-invasive device that could reliably detect subclinical AF episodes after an ESUS. Diagnostic yield was significatively higher when used within the first 30 days after the event, especially in selected patients.

  • Open Access

    Case Report: Aortic to right ventricular fistula after TAVR in a patient with transthyretin cardiac amyloidosis

    by Sergio Garcia-Gomez, Esther Gonzalez-Lopez, Juan Francisco Oteo

    Aortic to right ventricular fistula formation after transcatheter aortic valve replacement (TAVR) is a rare complication. We describe the first case of an aorto-RV fistula after TAVR, conservatively managed, in a patient with concomitant aortic stenosis and wild-type transthyretin cardiac amyloidosis. Given that the underlying pathology may have implications, transthyretin cardiac amyloidosis screening in patients undergoing TAVR is warranted.

  • Open Access

    Same-day discharge for atrial fibrillation ablation: use of suture-mediated vascular closure device

    by A Portoles-Hernandez, J Toquero-Ramos, S Garcia-Gomez, V Castro-Urda, E Garcia-Izquierdo, D Jimenez-Sanchez, M Segura-Dominguez, C Aguilera-Agudo, D Veloza-Urrea, I Fernandez-Lozano

    Funding Acknowledgements: Type of funding sources: None. Introduction: The most frequent complications of atrial fibrillation (AF) ablation procedures are those related to the vascular access site, which are associated with increased morbidity and length of hospital stay. Purpose: To assess the safety and efficacy of venous access site closure with a suture-mediated vascular closure device (SVD), as well as the feasibility of early mobilization and same-day discharge protocol after AF ablation procedures. Methods: We conducted a retrospective analysis of all consecutive AF ablation patients in whom a SVD was employed to achieve hemostasis after each venous puncture. The ablation was performed under conscious sedation, using 7 to 12-F introducer sheaths. Anticoagulation was uninterrupted but for the last dose prior to the procedure. Intraprocedural heparin was not reversed. Groin ultrasound was performed in the first 10 patients with adequate SVD deployment. Three conditions were required for the same-day discharge protocol application: 1) uncomplicated procedure, 2) successful SVD deployment and 3) adequate recovery. Recovery followed a three-phase protocol: bed rest (two hours), sitting (one hour) and ambulation. Follow-up included phone call and clinical examination. Patients were offered contact to the electrophysiologist if needed. Results: 63 ablation procedures with SVD closure were performed from May 2019 to October 2020, with a total of 132 access sites analysed. Patient characteristics are shown in the table. The SVD was successfully deployed in 125 (94.7%) and hemostasis immediately achieved. In the remaining 5.3%, failure was attributed to a deficient technique, which missed to advance the knot to the vein. First 10 patients were ultrasound evaluated 24 hours later (no early discharge), showing total absence of complications. 35 subsequent patients (55.6% of the remaining 53) were discharged the same day without ultrasound control. The remaining 18 stayed overnight for reasons not related to the access site (hemodynamic surveillance, initiation of antiarrhythmic drugs or loss of phrenic capture), allowing in any case early mobilization (three hours after the procedure). Mean follow-up was 272 ± 160 days, with no adverse events recorded. Conclusion: SVD are safe and effective in achieving rapid hemostasis, making the early mobilization and same-day discharge protocol after AF ablation feasible in selected patients. Age 63 (57-71) Male 46 (73%) Body mass index (kg/m²) 27,5 (24,2-31,6) Previous anticoagulation- Vitamin K antagonist- Direct oral anticoagulation 50 (79,4%)14 (28%)36 (72%)